跳转至内容
Merck
所有图片(1)

Key Documents

MAB8002

Sigma-Aldrich

抗-戊型肝炎病毒抗体,aa 434-457,克隆1E6

clone 1E6, Chemicon®, from mouse

别名:

HEV

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物源

mouse

品質等級

抗體表格

purified immunoglobulin

抗體產品種類

primary antibodies

無性繁殖

1E6, monoclonal

物種活性

human

製造商/商標名

Chemicon®

技術

ELISA: suitable
immunofluorescence: suitable
western blot: suitable

同型

IgG2b

運輸包裝

wet ice

特異性

ORF2.1,衣壳蛋白编码区

免疫原

表位:aa 434-457

應用

ELISA

免疫印迹

免疫荧光

最佳稀释度必须由最终用户确定。
抗戊型肝炎病毒抗体,aa 434-457,克隆1E6检测戊型肝炎病毒水平,&已发布&验证可用于WB、ELISA&IF。
研究子类别
传染病 - 病毒
研究类别
传染病

外觀

形式:纯化
液体形式,溶于0.02M PB和0.25M NaCl(pH 7.6)中。含0.1%叠氮化钠。

儲存和穩定性

自接收之日起,可在2°-8°C下储存长达12个月。

其他說明

浓度:关于批次特定浓度请参见检验报告。

法律資訊

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免責聲明

除非我们的目录或产品随附的其他公司文件中另有说明,否则我们的产品预期仅用于研究用途,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。

未找到合适的产品?  

试试我们的产品选型工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Fabian Z X Lean et al.
The Journal of general virology, 103(11) (2022-11-11)
Ferrets are widely used for experimental modelling of viral infections. However, background disease in ferrets could potentially confound intended experimental interpretation. Here we report the detection of a subclinical infection of ferret hepatitis E virus (FRHEV) within a colony sub-group
Martijn D B van de Garde et al.
Journal of virology, 90(9), 4394-4401 (2016-02-19)
Genotype 3 (gt3) hepatitis E virus (HEV) infections are emerging in Western countries. Immunosuppressed patients are at risk of chronic HEV infection and progressive liver damage, but no adequate model system currently mimics this disease course. Here we explore the
Wenhai Yu et al.
BMC infectious diseases, 18(1), 687-687 (2018-12-24)
Hepatitis E virus (HEV) is a leading cause of hepatitis worldwide. However, its infection biology and pathogenesis remain largely elusive. Furthermore, no proven medication is available for treating hepatitis E. Robust experimental models are urgently required to advance the research
Yunlong Li et al.
Antiviral research, 184, 104967-104967 (2020-11-03)
Exposure to hepatitis E virus (HEV) bears a high risk of developing chronic infection in immunocompromised patients, including organ transplant recipients and cancer patients. We aim to identify effective anti-HEV therapies through screening and repurposing safe-in-human broad-spectrum antiviral agents. In
Marie Pellerin et al.
Viruses, 13(3) (2021-04-04)
Hepatitis E virus (HEV) is considered as an emerging global health problem. In most cases, hepatitis E is a self-limiting disease and the virus is cleared spontaneously without the need of antiviral therapy. However, immunocompromised individuals can develop chronic infection

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门